Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $110 | ― | 28.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $216→$205 | ― | 10.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $15 | ― | 25.00% | Initiated | ||||
 | Veeva Systems | HOLD $261→$284 | ― | -0.40% | Reiterated | TD Cowen Sticks to Its Hold Rating for Veeva Systems (VEEV) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $2,500 | ― | 5.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $6 | ― | 43.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $170 | ― | 23.40% | Reiterated | ||||
nCino | BUY $28 | ― | -18.20% | Reiterated | KBW Remains a Buy on nCino (NCNO) | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $173 | ― | 29.70% | Initiated | ||||
| Ultragenyx Pharmaceutical | BUY $65 | ― | -3.50% | Initiated | Ultragenyx initiated with an Outperform at William Blair | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $10→$9.5 | ― | 6.30% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $8.5→$9.5 | ― | 6.30% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $167 | ― | 1.20% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120→$130 | ― | 17.10% | Reiterated | ||||
 | Sprout Social | BUY $32 | ― | -4.50% | Reiterated | Buy Rating Affirmed for Sprout Social: Leveraging Opportunities in Social Media Marketing | |||
| GDS Holdings | BUY $28.5 | ― | -17.60% | Reiterated | Daiwa sees opportunity to buy GDS after 'surprise' stock offering | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $198→$283 | ― | 5.70% | Reiterated | ||||
 | Prothena | SELL $22→$4 | ― | -3.40% | Downgraded | Prothena downgraded to Underperform from Neutral at BofA | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $14 | ― | 1.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $12.5→$21 | ― | 0.90% | Initiated | ||||
 | Xoma | BUY $104 | ― | -21.30% | Reiterated | XOMA's Strategic Expansion and Mezagitamab's Market Potential Drive Buy Rating | |||
| Bioline RX Ltd Sponsored ADR | BUY $26 | ― | -21.30% | Reiterated | BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18 | ― | 7.10% | Reiterated | ||||
| Washington Bancorp | HOLD $28 | ― | -3.80% | Initiated | Washington Trust initiated with a Neutral at BofA | |||
| Aura Biosciences Inc | BUY $22 | ― | -4.00% | Initiated | Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc | |||
 | NeuroPace | BUY $18 | ― | -13.30% | Initiated | Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85→$112 | ― | 10.60% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42 | ― | 1.00% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 5.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $92→$116 | ― | 10.60% | Reiterated | ||||
| Sonic Automotive | BUY $76 | ― | -28.30% | Initiated | Sonic Automotive initiated with a Buy at Benchmark | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45 | ― | 0.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $35 | ― | 0.40% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $7→$6 | ― | 3.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $87→$97 | ― | 4.80% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $160→$175 | ― | 1.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $75 | ― | 14.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115→$125 | ― | 12.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $171→$181 | ― | 24.40% | Reiterated | ||||
| Guidewire | BUY $230 | ― | -1.80% | Reiterated | Stifel Nicolaus Remains a Buy on Guidewire (GWRE) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 14.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 14.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42→$45 | ― | 14.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $29→$34 | ― | 28.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $54 | ― | 20.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $210 | ― | 16.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100→$110 | ― | 16.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $46→$50 | ― | 11.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $184 | ― | 10.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17 | ― | 14.40% | Reiterated |
Rows:
